600535.SS SHH
Tasly Pharmaceutical Group Co., Ltd
1W: +0.4%
1M: -4.6%
3M: +1.7%
YTD: -6.4%
1Y: -12.0%
3Y: +10.8%
5Y: +19.4%
¥14.00 ($2.09)
+0.26 (+1.89%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$15.3B
+2.4% ▲
5Y CAGR: -1.4%
Total Liabilities
$2.8B
-2.6% ▼
5Y CAGR: -7.4%
Shareholders Equity
$12.4B
+4.2% ▲
5Y CAGR: +0.7%
Cash & Investments
$2.8B
-19.6% ▼
5Y CAGR: +6.0%
Total Debt
$1.5B
+45.3% ▲
5Y CAGR: -11.9%
Net Debt
$49M
+102.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.3B | $3.1B | $4.5B | $3.0B | $1.4B |
| Short-Term Investments | $1.5B | $1.1B | $301M | $525M | $1.4B |
| Cash & ST Investments | $3.8B | $4.2B | $4.8B | $3.5B | $2.8B |
| Net Receivables | $3.8B | $3.3B | $2.2B | $2.0B | $2.5B |
| Inventory | $1.5B | $1.5B | $1.7B | $1.7B | $0 |
| Other Current Assets | $114M | $136M | $5M | $30M | $2.9B |
| Total Current Assets | $9.2B | $9.2B | $8.7B | $7.3B | $8.2B |
| Property, Plant & Equip. | $4.1B | $3.9B | $3.8B | $3.6B | $0 |
| Goodwill & Intangibles | $1.8B | $1.6B | $2.0B | $2.0B | $2.1B |
| Long-Term Investments | -$258M | $386M | $2.1B | $1.3B | $1.3B |
| Other Non-Current Assets | $1.6B | $1.3B | $66M | $618M | $3.7B |
| Total Non-Current Assets | $7.3B | $7.2B | $8.0B | $7.7B | $7.1B |
| Total Assets | $16.5B | $16.4B | $16.7B | $15.0B | $15.3B |
| — Liabilities — | |||||
| Accounts Payable | $266M | $373M | $497M | $607M | $377M |
| Short-Term Debt | $532M | $677M | $1.3B | $700M | $1.2B |
| Deferred Revenue | $479M | $155M | $0 | $0 | $0 |
| Other Current Liabilities | $430M | $713M | $136M | $771M | $7M |
| Total Current Liabilities | $1.9B | $2.1B | $2.4B | $2.3B | $2.3B |
| Long-Term Debt | $1.0B | $1.4B | $1.4B | $254M | $217M |
| Other Non-Current Liab. | $0 | -$282K | $160M | $203K | $0 |
| Total Non-Current Liabilities | $1.4B | $1.7B | $1.7B | $515M | $484M |
| Total Liabilities | $3.2B | $3.8B | $4.0B | $2.9B | $2.8B |
| — Equity — | |||||
| Common Stock | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Retained Earnings | $8.8B | $7.9B | $8.3B | $8.2B | $8.6B |
| Accumulated OCI | $1.5B | $1.8B | $1.8B | $1.9B | $1.9B |
| Total Stockholders Equity | $13.0B | $12.4B | $12.4B | $11.9B | $12.4B |
| Total Liabilities & Equity | $16.5B | $16.4B | $16.7B | $15.0B | $15.3B |
| — Key Metrics — | |||||
| Total Debt | $1.7B | $2.2B | $3.0B | $1.0B | $1.5B |
| Net Debt | -$610M | -$945M | -$1.5B | -$2.0B | $49M |
| Total Investments | $1.2B | $1.5B | $2.4B | $1.8B | $1.3B |